JLE

Epileptic Disorders

MENU

Pharmacokinetic data on brivaracetam, lacosamide and perampanel during pregnancy and lactation Volume 23, issue 2, April 2021

  • [1] Brivaracetam product information. https://www.ema.europa.eu/en/documents/product-information/briviact-epar-product-information_en.pdf (Accessed June 3, 2020).
  • [2] Lacosamide product information. https://www.ema.europa.eu/en/documents/product-information/lacosamide-accord-epar-product-information_en.pdf (Accessed June 3, 2020).
  • [3] Perampanel product information. https://www.ema.europa.eu/en/documents/product-information/fycompa-epar-product-information_en.pdf (Accessed June 3, 2020).
  • [4] Johnson E.J., Burke A.E., Wang A., Pennell P.B. Unintended pregnancy, prenatal care, newborn outcomes, and breastfeeding in women with epilepsy. Neurology. 2018;91:e1031-e1039. 11
  • [5] Reimers A., Brodtkorb E. Second-generation antiepileptic drugs and pregnancy: a guide for clinicians. Exp Rev Neurother. 2012;12:707-717. 6
  • [6] Tomson T., Johannessen Landmark C., Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia. 2013;54:405-414. 3
  • [7] Johannessen Landmark C., Johannessen S.I., Patsalos P.N. Therapeutic drug monitoring of antiepileptic drug: current status and future prospects. Exp Opin Drug Metab Toxicol. 2020;16:227-238. 3
  • [8] Svendsen T., Brodtkorb E., Baftiu A., Burns M.L., Johannessen S.I., Johannessen Landmark C. Therapeutic drug monitoring of lacosamide in Norway: Pharmacokinetic variability, clinical efficacy and tolerability. Neurochem Res. 2017;42:2077-2083. 7
  • [9] Ikemoto S., Hamano S.I., Hirata Y., Matsuura R., Koichihara R. Efficacy and serum concentrations of perampanel for treatment of drug-resistant epilepsy in children, adolescents, and young adults: comparison of patients younger and older than 12 years. Seizure. 2019;73:75-78.
  • [10] Hagemann A., Klimpel D., Bien C.G., Brandt C., May T.W. Influence of dose and antiepileptic comedication on brivaracetam serum concentrations in patients with epilepsy. Epilepsia. 2020;61:e43-e48. 5
  • [11] Voinescu P.E., Park S., Chen L.Q., Stowe Z.N., Newport D.J., Ritchie J.C. Antiepileptic drug clearances during pregnancy and clinical implications for women with epilepsy. Neurology. 2018;91:e1228-e1236. 13
  • [12] Westin A.A., Brekke M., Molden E., Skogvoll E., Castberg I., Spigset O. Treatment with antipsychotics in pregnancy: changes in drug disposition. Clin Pharmacol Ther. 2018;103:477-484. 3
  • [13] Abduljalil K., Pansari A., Jamei M. Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy. J Pharmacokinet Pharmacodyn. 2020;47:361-383. 4
  • [14] Schuck E., Rege B., Laurenza A., Williams B., Ferry J., Hussein Z. Predictions of the pharmacokinetic profile of perampanel during pregnancy using physiologically based pharmacokinetic (PBPK) modelling. Neurology. 2017;88:P3.237. Suppl 16
  • [15] Patsalos P.N., Zugman M., Lake C., James A., Ratnaraj N., Sander J.W. Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: A comparison of free non-protein-bound concentrations. Epilepsia. 2017;58:1234-1243. 7
  • [16] Hines R.N. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm. 2013;452:3-7. 1-2
  • [17] Allegaert K., van den Anker J. Ontogeny of phase I metabolism of drugs. J Clin Pharmacol. 2019;59:S33-41. Suppl 1
  • [18] Reimers A., Berg J.A., Burns M.L., Brodtkorb E., Johannessen S.I., Johannessen Landmark C. Reference ranges of antiepileptic drugs revisited-a practical approach to establish national guidelines. Clin Pharm Ther. 2018;12:271-280.